Cannabinoids for the Neuropsychiatric Symptoms of Dementia: A Systematic Review and Meta-Analysis.

ABSTRACT:

Background

In 2016, the global number of individuals living with dementia was 43.8 million, representing a 117% increase from 1990-mainly due to increases in aging and population growth. Up to 90% of individuals with dementia experience neuropsychiatric symptoms (NPS). However, the limitations of current treatments for NPS have drivent he search for safer pharmacotherapies-including cannabinoids.

Aim

To assess the efficacy and acceptability of cannabinoids for the treatment of NPS in individuals with dementia.

Design

Systematic review and meta-analysis of clinical trials.

Setting and participants

Of 6,902 papers, 9 were eligible (n = 205, 44% female, 78 ± 7 years, 85% Alzheimer disease). Trials were in North America and Europe and explored tetrahydrocann

SUBMITTER: Bahji A 

PROVIDER: S-EPMC7265608 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature